Gilead swings to $10.5B loss on $11.2B acquisition IPR&D and $1.75B Trodelvy impairment; revenue up 10.2%

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read

Key Changes

• high

  Net loss of $10.5B (diluted EPS -$8.45) vs. $2.0B profit a year ago, driven by $11.2B acquired IPR&D from Arcellx, Tubulis, and Ouro Medicines plus a $1.75B Trodelvy impairment.

  MD&A: Net loss verify on EDGAR →
• high

  Acquired IPR&D expense of $11.2B: $7.0B Arcellx, $3.1B Tubulis, $1.0B net Ouro Medicines ($1.9B gross less $860M Lakefront share).

  MD&A: Acquired IPR&D verify on EDGAR →
• high

  Discontinued Phase 3 EVOKE-03 study of Trodelvy in first-line NSCLC; wrote off remaining $1.75B NSCLC IPR&D asset.

  MD&A: Impairment verify on EDGAR →